OKYO Pharma (NASDAQ:OKYO – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a research report issued to clients and investors on Thursday, Benzinga reports. They presently have a $7.00 price objective on the stock. HC Wainwright’s target price would indicate a potential upside of 469.11% from the company’s previous close. HC Wainwright also issued estimates for OKYO Pharma’s Q2 2025 earnings at ($0.11) EPS, Q4 2025 earnings at ($0.09) EPS and FY2025 earnings at ($0.40) EPS.
OKYO Pharma Stock Performance
Shares of NASDAQ OKYO opened at $1.23 on Thursday. The business has a 50 day moving average price of $1.04 and a two-hundred day moving average price of $1.24. OKYO Pharma has a fifty-two week low of $0.81 and a fifty-two week high of $2.12.
About OKYO Pharma
Recommended Stories
- Five stocks we like better than OKYO Pharma
- What to Know About Investing in Penny Stocks
- 3 Undervalued Technology Stocks With Big Rebound Potential
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- NextEra Energy’s Strong Quarter Catches Wall Street’s Eye
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Goldman’s Lost Decade Forecast: These 3 Growth Stocks Can Win
Receive News & Ratings for OKYO Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OKYO Pharma and related companies with MarketBeat.com's FREE daily email newsletter.